Life Science Leader Magazine Supplements

CRO Leadership Awards 2017

The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute

Issue link:

Contents of this Issue


Page 37 of 45

CAPABILITIES COMPATIBILITY EXPERTISE QUALITY RELIABILITY K E Y W W W.C R O L E A D E R S H I PA W A R D S .C O M Company Profiles 2017 CRO LEADERSHIP AWARDS WINNERS 36 THE CRO LEADERSHIP AWARDS 2017 LIFESCIENCELEADER.COM SERVICES & CAPABILITIES: Regulatory consulting, pre-clinical testing services, medical device testing, clinical services THERAPEUTIC AREAS: anesthesia/respiratory, cardiology, dental, dermal wound care, diabetic, diagnostic imaging, ear/nose/throat, gastroen- terology, general/plastic surgery, IVD/companion diagnostics, neurosurgery, OB/GYN, oncology, opthalmology, orthopedics, peripheral vascular, regenerative medicine DRUG LIFE CYCLE STAGES: Research & Development: Discovery, Pre- Clinical, Clinical, Phase 1, Phase 2, Phase 3 Drug Substance Production: Primary Process Development, Drug Substance Production Formulated Drug Production: Dosage Form Development, Dosage Form Production MAIN SERVICE AREAS: Lab, Pre-Clinical, Full Service Clinical "NAMSA has a laser-like focus on accelerating medical device development and commercializa- tion efforts for thousands of clients worldwide. For over 50 years, our experienced teams have consis- tently delivered superior results throughout the full spectrum of product development - testing, clinical, and regulatory - time and time again. By combining the knowledge of our dedicated associates with our translational research approach, customers not only achieve clinical endpoints more quickly, but they also make more effective key commercializa- tion decisions that lead to success." JOHN GORSKI President & CEO CATEGORIES WON: NAMSA Toledo, Ohio Phone: 866-666-9455 Contact: Leah Davidson Email: Key locations: Toldeo, OH; Minneapolis, MN; Irvine, CA; Seoul, Korea; Tokyo, Japan; Shanghai, China; Beijing, China; Lyon, France; Frankfurt, Ger- many; Selby, United Kingdom; Petach Tikva, Israel INDIVIDUAL ATTRIBUTE AWARDS: meeting overall project timelines, offered innovative solutions, operational excellence, responsiveness SERVICES & CAPABILITIES: A multinational CRO offering comprehensive services to the pharma, biotech, and device industries. From Phase I to IV, we focus on delivering high-quality data, targeted enrollment & meeting projected timelines. THERAPEUTIC AREAS: cardiovascular, dermatol- ogy, device, endocrinology, gastroenterology, gynecology, hematology, infectious disease, neurology, oncology, ophthalmology, pediatrics, respiratory/allergy, rheumatology/inflammation, urology/nephrology DRUG LIFE CYCLE STAGES: Research & Development: Clinical, Phase 1, Phase 2, Phase 3 MAIN SERVICE AREAS: Full Service Clinical "We're honored to be recognized by the CRO Leadership Awards in each of the five core award categories again. These awards are a valida- tion of the dedication, flexibility, commitment to quality, and sponsor-first focus that our team strives for day-in and day-out. We appreciate that clinical trials are a significant investment for our sponsors, and we believe our mission – 'Helping Create a Healthier World' – reflects their goals and ambitions." DR. ZEV MUNK Chairman of the Board CATEGORIES WON: Pharm-Olam International Houston, Texas Phone: 713-559-7900 Contact: Mark Eberhardt Email: Key locations: Houston, TX; Ascot, UK INDIVIDUAL ATTRIBUTE AWARDS: data quality, meeting overall project timelines, offered innovative solutions, operational excellence, responsiveness, tech- nology for real-time access to data SERVICES & CAPABILITIES: Phase I, Phase II-IIIb, post-approval. Bioanalytical, GMP, central, and vaccine sciences labs, biomarker services. Consulting services: product development, bio- similars, adaptive trial design, pediatrics, rare dis- eases, cardiovascular outcomes, medical devices. THERAPEUTIC AREAS: cardiovascular, critical care, dermatology, endocrine & metabolics, gastroenter- ology, hematology & oncology, immunology, infec- tious diseases, neuroscience, ophthalmology, rare diseases, respiratory, urology DRUG LIFE CYCLE STAGES: Research & Development: Pre-Clinical, Clinical, Phase 1, Phase 2, Phase 3 MAIN SERVICE AREAS: Lab, Full Service Clinical "PPD is committed to accelerating the generation of evidence necessary for our customers to bring life-changing therapies to society. Pharmaceutical and biotechnology clients can rely on our exper- tise and tailored, quality-first services across Phase I-IV and post-approval research, with integrated and comprehensive laboratory ser- vices and industry leadership in site and patient relationships. Our strategically expanded service offerings help ensure our clients' evolving needs are met with precision and high quality across the drug development continuum." DAVID SIMMONS Chairman & CEO CATEGORIES WON: PPD Wilmington North Carolina Phone: 910-251-0081 Contact: PPD Business Development Email: Key locations: Wilmington, NC; Research Triangle, NC; Madison, WI; Austin, TX; Richmond, VA; Europe; China; Japan INDIVIDUAL ATTRIBUTE AWARDS: operational excellence, responsiveness

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine Supplements - CRO Leadership Awards 2017